

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 51951

**Title:** Durable response to pulsatile icotinib for CNS metastases from EGFR-mutated non-small cell lung cancer: a case report

**Reviewer's code:** 02446061

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Professor, Research Scientist

**Reviewer's country:** Mexico

**Author's country:** China

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2019-11-20 15:37

**Reviewer performed review:** 2019-11-27 01:41

**Review time:** 6 Days and 10 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The manuscript is attractive. The presented case is interesting. a) Please be specific in the conclusion. It must not be speculative. Then, please declare 'the therapy was effective in this case' as it is the case... then, the collection of additional data for analysis should be propiciated. "pulsatile high-dose icotinib was a well-tolerated and effective treatment for this case" b) Detailed information about the improvement of patient after treatment should be presented. c) Recent manuscripts are interesting to this case: - Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report. Wang J, Chen J. BMC Cancer. 2019 Feb 8;19(1):131. - Icotinib and whole-brain radiotherapy for the treatment in patients with brain metastases from EGFR-mutant nonsmall cell lung cancer: A retrospective study. Jiang AY, Zhang J, Luo HL, Gao F, Lv YF. Medicine (Baltimore). 2018 Apr;97(15):e0312. - Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases. Fan Y, Xu Y, Gong L, Fang L, Lu H, Qin J, Han N, Xie F, Qiu G, Huang Z. Sci Rep. 2017 Mar 23;7:45193. I suggest to analyze their content to enrich this case report.

## INITIAL REVIEW OF THE MANUSCRIPT

### *Google Search:*

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☒ No

### *BPG Search:*

- ☐ The same title
- ☐ Duplicate publication



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** bpgoffice@wjgnet.com  
**<https://www.wjgnet.com>**

[ ] Plagiarism

[ Y ] No